Agile Therapeutics Gets a Buy Rating from RBC Capital

By Carrie Williams

In a report issued on July 14, Randall Stanicky from RBC Capital reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX), with a price target of $8. The company’s shares closed on Friday at $3.98.

According to, Stanicky is ranked 0 out of 5 stars with an average return of -7.7% and a 36.7% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Eagle Pharmaceuticals, and Jazz Pharmaceuticals.

Agile Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.50.

Based on Agile Therapeutics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $0 and GAAP net loss of $7.52 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $8.42 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. engages in the development and commercialization of new prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company was founded on December 22, 1997 and is headquartered in Princeton, NJ.